Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chondrosarcoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chondrosarcoma - Pipeline Review, H1 2015', provides an overview of the Chondrosarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chondrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chondrosarcoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chondrosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chondrosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chondrosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Chondrosarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Chondrosarcoma - Overview 7 Pipeline Products for Chondrosarcoma - Comparative Analysis 8 Chondrosarcoma - Therapeutics under Development by Companies 9 Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 10 Chondrosarcoma - Pipeline Products Glance 11 Clinical Stage Products 11 Chondrosarcoma - Products under Development by Companies 12 Chondrosarcoma - Products under Investigation by Universities/Institutes 13 Chondrosarcoma - Companies Involved in Therapeutics Development 14 Agios Pharmaceuticals, Inc. 14 Celgene Corporation 15 CytRx Corporation 16 Karyopharm Therapeutics, Inc. 17 Merck & Co., Inc. 18 Novartis AG 19 Chondrosarcoma - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 AG-120 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 aldoxorubicin hydrochloride - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CC-90007 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 pazopanib hydrochloride - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pembrolizumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 selinexor - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Chondrosarcoma - Recent Pipeline Updates 56 Chondrosarcoma - Dormant Projects 93 Chondrosarcoma - Discontinued Products 94 Chondrosarcoma - Product Development Milestones 95 Featured News & Press Releases 95 May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 95 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Chondrosarcoma, H1 2015 7 Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 14 Chondrosarcoma - Pipeline by Celgene Corporation, H1 2015 15 Chondrosarcoma - Pipeline by CytRx Corporation, H1 2015 16 Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17 Chondrosarcoma - Pipeline by Merck & Co., Inc., H1 2015 18 Chondrosarcoma - Pipeline by Novartis AG, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Chondrosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 56 Chondrosarcoma - Dormant Projects, H1 2015 93 Chondrosarcoma - Discontinued Products, H1 2015 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.